Results 81 to 90 of about 31,452 (261)
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Developability considerations for bispecific and multispecific antibodies
mAbsBispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash +9 more
doaj +1 more source
Journal of Clinical Laboratory Analysis, EarlyView.This graphical abstract illustrates the prognostic significance of systemic inflammatory markers in Multiple Myeloma (MM). The left panel depicts the immunosuppressive tumor microenvironment, where abundant neutrophils and M2 macrophages promote MM cell survival while lymphocytes are depleted.
Lihong Zhang, Bing Ma, Jingyu Zhang
wiley +1 more source
European Journal of Case Reports in Internal MedicineBackground: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL).
Oscar F. Borja-Montes +6 more
doaj +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu +5 more
wiley +1 more source
Medicinal Research Reviews, EarlyView.ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu +2 more
wiley +1 more source
Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts
Muscle &Nerve, EarlyView.ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman +3 more
wiley +1 more source
The Journal of Pathology, EarlyView.Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi +8 more
wiley +1 more source
Cell Reports MedicineSummary: IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) peptide ...
Juanita S. Lopez +12 more
doaj +1 more source